In this study we used WES to disclose variants contributing to BC increased risk in patients fulfilling stringent clinical criteria indicating a genetic predisposition to BC and that were negative for pathogenic variants in four major BC genes (BRCA1/2, TP53, and CHEK2 1100delC). This evidence concerns the gene TP53 and breast cancer.